Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | HPGD | P15428 | 8/20 | 0.57 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20839167 | 0.88 | ALDH1A1 (0.57) | ALDH1A1HPGDALDH2KDM4ERECQL | |
| SCHEMBL20847991 | 0.88 | ALDH1A1 (0.57) | ALDH1A1HPGDALDH2KDM4ERECQL | |
| SCHEMBL30762863 | 0.88 | ALDH1A1 (0.57) | ALDH1A1HPGDALDH2KDM4ERECQL | |
| SCHEMBL30360979 | 0.88 | ALDH1A1 (0.57) | ALDH1A1HPGDALDH2KDM4ERECQL | |
| SCHEMBL26112351 | 0.88 | ALDH1A1 (0.64) | ALDH1A1HPGDALDH2KDM4ERECQL | |
| SCHEMBL26112347 | 0.88 | ALDH1A1 (0.64) | ALDH1A1HPGDALDH2KDM4ERECQL | |
| SCHEMBL20839106 | 0.87 | ALDH1A1 (0.62) | ALDH1A1HPGDALDH2KDM4ERECQL | |
| SCHEMBL30762868 | 0.87 | ALDH1A1 (0.62) | ALDH1A1HPGDALDH2KDM4ERECQL | |
| SCHEMBL31637547 | 0.82 | ALDH1A1 (0.57) | ALDH1A1HPGDALDH2KDM4ERECQL | |
| SCHEMBL21629579 | 0.82 | ALDH1A1 (0.66) | ALDH1A1HPGDALDH2KDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739696-A1 | MITOCHONDRIA SPECIFIC TRANSCRIPTION INHIBITOR COMPOUNDS | Lunella Biotech, Inc. (CA) | 2026-05-13 | — | — | EP | disclosed |
| EP-4720079-A1 | MITOCHONDRIA SPECIFIC TRANSCRIPTION INHIBITORS | Lunella Biotech, Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| US-20250206713-A1 | 2-[(2-OXO-4-PHENYL-2H-CHROMEN-7-YL)OXY] PROPANAMIDO DERIVATIVES | LUNELLA BIOTECH, INC. (CA) | 2025-06-26 | — | — | US | disclosed |
| EP-4499622-A1 | 2-[(2-OXO-4-PHENYL-2H-CHROMEN-7-YL)OXY] PROPANAMIDO DERIVATIVES | Lunella Biotech, Inc. (CA) | 2025-02-05 | — | — | EP | disclosed |
| WO-2025008773-A1 | MITOCHONDRIA SPECIFIC TRANSCRIPTION INHIBITOR COMPOUNDS | LUNELLA BIOTECH, INC. (CA) | 2025-01-09 | — | — | WO | disclosed |
| WO-2024246717-A1 | MITOCHONDRIA SPECIFIC TRANSCRIPTION INHIBITORS | LUNELLA BIOTECH, INC. (CA) | 2024-12-05 | — | — | WO | disclosed |
| WO-2023187561-A1 | 2-[(2-OXO-4-PHENYL-2H-CHROMEN-7-YL)OXY] PROPANAMIDO DERIVATIVES | LUNELLA BIOTECH, INC. (CA) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206713-A1 | 2-[(2-OXO-4-PHENYL-2H-CHROMEN-7-YL)OXY] PROPANAMIDO DERIVATIVES | POLRMT, TFAM, POLM | ALDH1A1 1696/4885HPGD 3669/4885ALDH2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.